Why Hims & Hers Health Are Falling Monday - Hims & Hers Health (NYSE:HIMS)
- On Tuesday, Hims & Hers Health stock plummeted after the firm reported first-quarter revenue of $608 million, missing the $616.9 million consensus estimate from Monday's earnings release.
- The company incurred $33 million in costs this quarter during a 'strategic pivot' away from compounded GLP-1 drugs toward branded treatments from Eli Lilly and Novo Nordisk.
- Gross margins slipped to 65% from 73% as the firm reduces reliance on compounded GLP-1s, a move analysts described as a 'transition' phase for the telehealth provider.
- JPMorgan analysts cut their price target to $33 from $35 due to margin pressure, while Canaccord raised its target to $32 from $30, framing results as a temporary speed bump.
- Management raised full-year 2026 revenue guidance to $2.8 billion to $3 billion, with CEO Andrew Dudum asserting 2026 is a 'defining year' for the platform's expansion into new categories.
17 Articles
17 Articles
Hims' sales miss as telehealth competition grows
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. My colleagues today launched a series investigating one of the biggest public health crises in the U.S. — the alcohol epidemic. Their stories will examine factors ranging from the influence of the alcohol industry to the gaps in treatment options for addiction. Read part 1 of the series here. The need-to-know …
JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story
The post JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story appeared first on 24/7 Wall St.. Quick Read JPMorgan cut Hims & Hers Health’s (HIMS) price target to $33 from $35 on margin pressure from its shift away from higher-margin compounded to branded GLP-1 medications. The analyst who called NVIDIA in 2010 just named his top 10 stocks and Hims & Hers wasn't one of them. Get them here FREE. Shares of Hims & Hers…
Coverage Details
Bias Distribution
- 42% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
